CureVac is ready to compete in the big leagues with its vaccines, according to a UBS analyst who says the soaring stock has more room to rise.
UBS analyst Eliana Merle upgraded the shares (ticker: CVAC) to Buy from Neutral and raised her 12-month target for the stocks price to $18 from $8 on Thursday. Merle listed recent clinical trial data and the biopharmaceutical company’s ability to gain market share as reasons for the upgrade.
Source: finance.yahoo.com
Related posts:
Billionaire investor Barry Sternlicht says inflation is going to ‘drop hard’—just look at rents
My 5 Top Dividend Stocks to Buy Hand Over Fist in 2024
Medicare Trust Fund Under Fire: Critics Accuse VP Harris Of 'Highway Robbery' For Allegedly 'Violati...
Bonds Are Back. Here Are the Income-Generating Funds to Buy Now.
Billionaire Paul Singer Says Recession Is Likely, but Stays Heavily Invested in These 2 Stocks